A2A Pharmaceuticals, Inc.'s Form 4/A amendment
AmendedBiomea Fusion, Inc. (BMEA) · filed Apr 6, 2023
- Accession no.
- 0001859061-23-000003
- Filed
- Apr 6, 2023
- Trade date
- Mar 31, 2023
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Mar 31, 2023
This filing lists 1 non-derivative transaction. Open-market sales total $6.25M. It was filed 6 days after the trade.
This amendment replaces 0001859061-23-000002 (filed Apr 6, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| A2A Pharmaceuticals, Inc.CIK 0001859061 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2023 | Common Stock | SSaleDisposed | −200,000 | $31.25F1 | −$6,250,000 | 4,100,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64. Additional details of the individual transactions are available upon request.
Referenced by the price of 1 transaction in Table I.